Stock Groups

EU drug regulator aims to conclude Merck COVID-19 antiviral pill approval by the end of 2021 -Breaking

by Mike Robinson

[ad_1]

© Reuters. FILE PHOTO: Signage is seen at the Merck & Co. headquarters in Kenilworth, New Jersey, U.S., November 13, 2021. REUTERS/Andrew Kelly

(Reuters) – The European Medicine Agency has approved Merck’s antiviral medication molnupiravir. This was developed by Ridgeback Therapeutics.

Marco Cavaleri stated in a press briefing, that there was a need for a thorough review of the use Pfizer (NYSE:) The COVID-19 vaccine for 5- to 11-year olds in the United States should be recommended by this month, and perhaps as early as next week.

Disclaimer: Fusion MediaWe remind you that this site does not contain accurate or real-time data. CFDs include stocks, futures, indexes and Forex. Prices are provided not by the exchanges. Market makers provide them. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.

Fusion MediaFusion Media and anyone associated with it will not assume any responsibility for losses or damages arising from the use of this website’s data including quotes and charts. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.



[ad_2]